

(19)



(11)

EP 2 012 128 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 153(4) EPC

(43) Date of publication:
07.01.2009 Bulletin 2009/02

(51) Int Cl.:
G01N 33/574 (2006.01)

(21) Application number: **07740484.6**

(86) International application number:
PCT/JP2007/057048

(22) Date of filing: **30.03.2007**

(87) International publication number:
WO 2007/119606 (25.10.2007 Gazette 2007/43)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(72) Inventors:
• **RYO, Akihide**
Yokohama-shi, Kanagawa 236-0004 (JP)
• **AOKI, Ichiro**
Yokohama-shi, Kanagawa 236-0004 (JP)
• **SASAKI, Takeshi**
Yokohama-shi, Kanagawa 232-0024 (JP)

(30) Priority: **05.04.2006 JP 2006104315**

(74) Representative: **Kador, Ulrich**
Kador & Partner
Corneliusstrasse 15
80469 München (DE)

(71) Applicant: **Yokohama City University**
Yokohama-shi
Kanagawa 236-0027 (JP)

(54) **METHOD FOR DETERMINATION OF PROGNOSIS OF PROSTATE CANCER, AND DIAGNOSTIC AGENT FOR USE IN THE METHOD**

(57) A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed. It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the

bone metastasis was observed than in the cases where bone metastasis was not observed. Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human.




Fig.1

EP 2 012 128 A1

Description

Technical Field

5 **[0001]** The present invention relates to a method for determining probability that a prostate cancer will metastasize, and to a diagnostic reagent therefor.

Background Art

10 **[0002]** In the U.S., prostate cancer has the highest prevalence among cancers in males. In Japan too, the prevalence of the prostate cancer is consistently increasing due to the change of lifestyle such as westernization of dietary life (Non-patent Literature 1). Since no specific symptoms are manifested in the early stage of prostate cancer, and since prostate cancer is often complicated with benign prostatic hyperplasia, the symptoms similar to those of benign prostatic hyperplasia, and dysuria, nocturia, urinary urgency and the like are found in some cases. Therefore, recently, even though
 15 no symptom is observed, most of prostate cancer is detected by measurement of PSA prostate-specific antigen in the blood in medical examination or health screening. Prostate cancer is characterized by high frequency of metastasis, and in some cases, advanced cancer is found because of low back pain due to bone metastasis (Non-patent Literature 2).
[0003] As the factor deciding the prognosis of prostate cancer, stage (in the following) thereof before surgery is important.

20 Stage A: cases where prostate cancer was accidentally found in surgery of benign prostatic hyperplasia or bladder cancer
 Stage B: cases where the cancer is confined in the prostate
 Stage C: cases where the cancer is not metastasized to other organs (such as bone, lymph node, lung and liver),
 25 but the cancer is exposed to the outside of the coating membrane (the membrane coating the periphery of prostate)
 Stage D: cases where the cancer is metastasized to other organs such as bone and lymph node

[0004] For the cases of Stage A to Stage C, basically, total extirpation of prostate is carried out. However, in a considerable number of cases, recurrence of the cancer within several years after the surgery is observed. Especially,
 30 refractoriness to hormone therapy and metastasis are important factors which aggravate the survival prognosis, so that to estimate these factors at an early stage has a great clinical significance in the selection of therapy or treatment of the patient. However, up to now, no molecular marker is known which enables to estimate the prognosis of prostate cancer, especially the metastasis thereof, at an early stage.

[0005] On the other hand, it is known that blockade of NF- κ B (nuclear factor, NF)- κ B activity, which is one of the transcription factors, inhibits angiogenesis, infiltration and metastasis in human prostate cancer (Non-patent Literature 3).
 35 More particularly, Non-patent Literature 3 discloses that when a mutated I κ B α gene having an activity to inhibit NF- κ B activity was introduced into metastatic human prostate cancer cells PC-3M and the cells were transplanted to nude mice, angiogenesis, infiltration and metastasis were inhibited in the group wherein NF- κ B activity was reduced by the introduction of the mutated I κ B α gene when compared with the group wherein the human prostate cancer cells PC-3M into
 40 which the mutated I κ B α gene was not introduced were transplanted. Non-patent Literature 4 discloses that in prostate cancer cells, expression of NF- κ B significantly occurs in the nuclei. Non-patent Literature 5 discloses that by the action of Pin1 which is a type of peptidyl-prolyl isomerase that specifically acts on the sequence of phosphorylated threonine or serine and subsequent proline, which sequence exists in a protein, on p65/RelA which is a subunit of NF- κ B and in which the 254th amino acid threonine is phosphorylated, the binding of NF- κ B-p65/RelA to I κ B α that is an inhibition
 45 factor of NF- κ B is inhibited, so that nuclear accumulation and stability of NF- κ B-p65/RelA are increased and, in turn, the NF- κ B activity is increased.

[0006]

50 Non-patent Literature 1: Wakai K. Descriptive epidemiology of prostate cancer in Japan and Western countries Nippon Rinsho. 2005 Feb;63(2):207-12.

Non-patent Literature 2: Loberg RD, Gayed BA, Olson KB, Pienta KJ. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem. 2005 Oct 15;96(3):439-46.

55 Non-patent Literature 3: Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001 Jul 12;20(31):4188-97.

Non-patent Literature 4: Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005 Oct 31;

93(9):1019-23.

Non-patent Literature 5: Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S, Lu KP. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 2003 Dec;12(6):1413-26.

5

Disclosure of the Invention

Problems to be Solved by the Invention

10 **[0007]** An object of the present invention is to provide a method for determining probability that a prostate cancer will metastasize and a diagnostic reagent therefor. Means for Solving the Problems

[0008] The present inventors intensively studied to discover that the percentage that NF- κ B-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed, and that the probability that a prostate cancer will metastasize can be determined at an early stage by examining whether the 254th amino acid threonine in NF- κ B-p65/RelA is phosphorylated or not, thereby completing the present invention.

15 **[0009]** That is, the present invention provides a method for determining probability that a prostate cancer will metastasize, the method comprising measuring human NF- κ B-p65/RelA in which 254th amino acid threonine is phosphorylated, the human NF- κ B-p65/RelA being contained in a prostate tissue separated from human. The present invention also provides a diagnostic reagent for determining probability that a prostate cancer will metastasize, the reagent comprising an antibody or an antigen-binding fragment thereof, the antibody undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is phosphorylated but not undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is not phosphorylated.

25 Effects of the Invention

[0010] By the present invention, means by which the probability that a prostate cancer will metastasize can be determined at an early stage was first provided. By the present invention, since the probability that a prostate cancer will metastasize can be determined at an early stage, therapy or treatment of the patient can be properly selected, so that the present invention is expected to greatly contribute to the therapy of prostate cancer.

Brief Description of the Drawings

[Fig. 1]

35

[0011] A figure which comparatively shows the ratio of strongly positive, positive and negative results of immunohistochemical staining of prostate tissues in the cases where bone metastasis was observed and not observed, respectively, which immunohistochemical staining was carried in the Example of the present invention. Best Mode for Carrying out the Invention

40 **[0012]** NF- κ B is a transcription factor which is expressed widely in most cells. Since it is expressed in nuclei of cells, it is called nuclear factor. NF- κ B-p65/RelA is one of the subunits of NF- κ B. The amino acid sequence of human NF- κ B-p65/RelA and the cDNA sequence encoding it are known, and are shown in GenBank Accession No. M62399. The base sequence of the cDNA of human NF- κ B-p65/RelA and the amino acid sequence encoded thereby are shown in SEQ ID NO: 1 in SEQUENCE LISTING, and the amino acid sequence alone is shown in SEQ ID NO: 2.

45 **[0013]** In the method of the present invention, the human NF- κ B-p65/RelA in which 254th amino acid threonine is phosphorylated (hereinafter also referred to as "254 phosphorylated NF- κ B-p65/RelA" for convenience). The term "threonine is phosphorylated" means that the hydroxyl group in the side chain of threonine is converted to a phosphoric acid ester. Phosphorylated threonine *per se* is well-known. In the present invention, the term "measure" includes any of detection, semi-quantification and quantification. The term "measure the 254 phosphorylated NF- κ B-p65/RelA" means to measure the 254 phosphorylated NF- κ B-p65/RelA distinctly from the NF- κ B-p65/RelA whose 254th threonine is not phosphorylated (hereinafter also referred to as "254 unphosphorylated NF- κ B-p65/RelA" for short).

50 **[0014]** An example of the preferred method for measuring the 254 phosphorylated NF- κ B-p65/RelA is an immunoassay using an antibody (hereinafter also referred to as "254 phosphorylated NF- κ B-p65/RelA-specific antibody") or an antigen-binding fragment thereof, which antibody undergoes antigen-antibody reaction with 254 phosphorylated NF- κ B-p65/RelA but does not undergo antigen-antibody reaction with 254 unphosphorylated NF- κ B-p65/RelA.

55 **[0015]** The 254 phosphorylated NF- κ B-p65/RelA-specific antibody may be a polyclonal antibody or a monoclonal antibody. The 254 phosphorylated NF- κ B-p65/RelA-specific polyclonal antibody can be obtained by preparing a polyclonal antibody by a conventional method using as an immunogen 254 phosphorylated NF- κ B-p65/RelA or a fragment

thereof containing the 254th threonine; and removing, from the obtained polyclonal antibody, by adsorption the antibodies which also undergo antigen-antibody reaction with 254 unphosphorylated NF- κ B-p65/RelA (see the Example below). The monoclonal antibody can be obtained by preparing hybridomas each producing an anti-254 phosphorylated NF- κ B-p65/RelA monoclonal antibody by a conventional method using as an immunogen 254 phosphorylated NF- κ B-p65/RelA or a fragment thereof containing the 254th threonine; selecting, from the obtained hybridomas, those producing the 254 phosphorylated NF- κ B-p65/RelA-specific antibody; culturing the selected hybridomas *in vitro* or in abdominal cavity of an animal, or the like; and recovering the 254 phosphorylated NF- κ B-p65/RelA-specific antibody produced by the hybridomas from the culture medium or ascites. In the immunoassay, the 254 phosphorylated NF- κ B-p65/RelA-specific antibody may be used, or a fragment thereof having a binding activity to the antigen, such as Fab fragment or F(ab')₂ fragment (in the present invention, referred to as "antigen-binding fragment") may also be used.

[0016] As the immunogen used for the preparation of the anti-254 phosphorylated NF- κ B-p65/RelA antibody, the whole molecule of 254 phosphorylated NF- κ B-p65/RelA or a fragment thereof containing the 254th threonine may be used, as mentioned above. In the latter case, the size of the peptide fragment is preferably not less than 10 amino acids, more preferably not less than 12 amino acids. Since a 254 phosphorylated NF- κ B-p65/RelA-specific antibody was obtained in the Example described below using a fragment having 12 amino acids ((VFRT(PO3H2)PPYADPSC) (SEQ ID NO: 3), the "(PO3H2)" after T means that the hydroxyl group in the side chain of this threonine (T) is phosphorylated), a size of 12 amino acids is sufficient. Needless to say, however, those having a longer size (the longest is the whole molecule of 254 phosphorylated NF- κ B-p65/RelA) can also be used as the immunogen. The peptide fragment of the 254 phosphorylated NF- κ B-p65/RelA which can be used as the immunogen can easily be chemically synthesized using a commercially available peptide synthesizer. Since the phosphorylated threonine *per se* is commercially available, a peptide fragment containing the phosphorylated threonine as the 254th threonine can be synthesized by using the commercially available threonine as a material in the step of binding the 254th threonine when the peptide is chemically synthesized. In cases where a peptide fragment is used as the immunogen, the peptide fragment may be used as the immunogen as it is, or the peptide fragment bound to a protein carrier such as bovine serum albumin, casein or keyhole limpet hemocyanin, may be used as the immunogen. Since a 254 phosphorylated NF- κ B-p65/RelA-specific antibody was obtained in the Example below by administering a peptide fragment consisting of 12 amino acids as it is, binding to the carrier protein is not indispensable.

[0017] The immunoassay can be carried out by immunohistochemical staining to a prostate tissue separated from the living body, or by a well-known immunoassay such as sandwich method, competition method or agglutination method using as a test sample a cell homogenate of a prostate tissue separated from the living body or the purified or partially purified product thereof containing NF- κ B-p65/RelA. Among these methods, immunohistochemical staining is preferred. The immunohistochemical staining can be carried out by a conventional method except that the 254 phosphorylated NF- κ B-p65/RelA-specific antibody is used as the antibody (see the Example below). Since a kit for immunohistochemical staining is commercially available, the immunohistochemical staining can be easily carried out using the commercially available kit and the above-described 254 phosphorylated NF- κ B-p65/RelA-specific antibody as the antibody.

[0018] As will be concretely described in the Example below, in the prostate cancer tissue metastasized to bone, the percentage that the reactivity with the 254 phosphorylated NF- κ B-p65/RelA-specific antibody is positive (positive rate) was statistically significantly higher than in the cases where bone metastasis was not observed. Moreover, among the cases where the 254 phosphorylated NF- κ B-p65/RelA was positive, in the cases where the abundance of 254 phosphorylated NF- κ B-p65/RelA was especially high (in the cases where the immunohistochemical staining was strongly positive), the percentage of bone metastasis was especially high. Further, in most cases where bone metastasis occurred, the immunohistochemical staining was positive irrespective of the histological malignancy (Gleason grade). These results show that the 254 phosphorylated NF- κ B-p65/RelA can be utilized as a prostate cancer metastasis marker indicating the probability of metastasis of prostate cancer, and whether metastasis will occur in the future or not can be estimated irrespective of the histological malignancy.

[0019] The present invention will now be described more concretely by way of an example thereof. However, the present invention is not restricted to the Example below. Example

Materials and Methods

1. Preparation of 254 phosphorylated NF- κ B-p65/RelA-specific Antibody

[0020] A phosphorylated peptide (VFRT(PO3H2)PPYADPSC) (SEQ ID NO: 3) which was a fragment of p65/RelA, containing the 254th threonine (12 amino acids from the 251st valine to 262nd cysteine) wherein the 254th threonine had a phosphate group attached thereto was chemically synthesized using a peptide synthesizer. As the phosphorylated threonine to which a phosphate group was added, a commercially available product was used. The obtained peptide fragment was mixed with an equal amount of Freund complete adjuvant (first immunization) or Freund incomplete adjuvant (second and subsequent immunization), and an emulsion was prepared by sonication. The resulting viscose

EP 2 012 128 A1

emulsion was subcutaneously administered to the back of a rabbit (New Zealand white rabbit). The immunization was conducted totally 4 times at 2-week intervals. At the time of third immunization, a small amount of the antigen protein was sampled, and antibody titer was measured by ELISA. Two weeks after the fourth immunization, the total blood was collected from the carotid artery under anesthesia with ketamine-xylazine. The collected blood was left to stand at room temperature for 1 hour, and then at 4°C overnight, followed by centrifugation at 3000 rpm for 10 minutes to obtain a serum.

[0021] Using a commercially available antibody-purification kit (Amersham Bio., HiTrap Protein A HP), antibody was purified from the obtained antiserum. The buffers used were as follows:

Binding buffer	20 mM sodium phosphate, pH7.0
Elution buffer	0.1 M sodium citrate, pH3.0
Neutralization buffer	1.0 M Tris-HCl, pH9.0

[0022] Concrete purification operation was as follows:

(1) Preparation of column: A syringe was connected without introducing bubbles into the column, and 25 mL of ultrapure water was applied at a rate of 5 drops/second.

(2) Equilibration of Column: 25 mL of binding buffer was applied at a rate of 5 drops/second.

(3) Addition of sample: The prepared sample (dilution of antiserum) was applied at a rate of 5 drops/second, and the adsorbed components were washed, followed by application of 25 mL of binding buffer at a rate of 5 drops/second.

(4) Elution of antibody: 25 mL of elution buffer was applied at a rate of 5 drops/second, the eluted solution was collected in 3 mL fractions (300 µL of neutralization buffer was added to each collection tube), the concentration of each of the eluted fractions was measured, the absorbance at 280 nm of each fraction was measured, the antibody fraction was recovered and dialyzed to PBS(-) overnight to exchange the buffer.

[0023] From the obtained polyclonal antibody, the antibody which underwent antigen-antibody reaction also with 254 unphosphorylated NF-κB-p65/RelA was removed by adsorption. More particularly, a biotinylated 254 unphosphorylated NF-κB-p65/RelA (VFRTPPYADPSC) (SEQ ID NO: 3) chemically synthesized with a peptide synthesizer was bound to commercially available streptavidin-magnetic beads (amount of total bound antigen: 0.01 mg; amount of beads: 0.2 mg), and the beads were mixed with 10-fold diluted antibody solution (0.3 mL) at 4°C for 2 hours. Then the non-specific antibody adsorbed to the unphosphorylated peptide was removed using a magnet, and the supernatant was recovered to obtain a 254 phosphorylated NF-κB-p65/RelA-specific antibody.

2. Immunohistochemical Staining

[0024] Using a commercially available immunohistochemical staining kit (VECTASTAIN ABC Kit), immunohistochemical staining with the 254 phosphorylated NF-κB-p65/RelA-specific antibody obtained in the above-described 1 was performed on prostate tissues separated from patients. The concrete operation of the immunohistochemical staining was as follows:

[0025]

(1) Deparaffinization and hydrophilization of each tissue section with xylene and ethanol

(2) Washing twice (each for 5 minutes) with 100 mL each of Tris buffered physiological saline (TBS).

(3) Inactivation of endogenous peroxidase (1 hour) with 60 mL of TBS supplemented with 2 mL of 30% H₂O₂ (1%)

(4) Washing twice (each for 5 minutes) with 100 mL each of TBS.

(5) Blocking (1 hour) with goat serum in TBS (3 mL) (final concentration: 10%)

(6) Washing once (for 5 minutes) with 100 mL of TBST (0.1% Tween 20 (trade name)-containing TBS)

(7) Primary antibody (254 phosphorylated NF-κB-p65/RelA-specific antibody prepared in the above-described 1) diluted (50-fold to 150-fold) with the blocking solution was added to the sample and the resultant was left to stand at room temperature for 2 hours or at 4°C overnight.

(8) Washing twice (each for 5 minutes) with 100 mL each of TBS

(9) Secondary antibody (500 µL of TBS supplemented with 2 µL of biotinylated secondary antibody (goat anti-rabbit IgG antibody, included in the kit)) was added to the sample and the resultant was allowed to react for 2 hours.

(10) Washing twice (each for 5 minutes) with 100 mL each of TBS

(11) Preparation of AB solution (10 mL of TBS supplemented with 2 drops each of A: avidin solution (C solution) and B: biotinylated peroxidase (D solution)). AB solution was prepared 30 minutes before use and allowed to react.

(12) AB solution is added to the sample, and the resultant is allowed to react for 2 hours.

(13) Washing twice (each for 5 minutes) with 100 mL each of TBS

EP 2 012 128 A1

(14) DAB solution (TBS (5 mL) containing 50 μg (10 $\mu\text{g}/\text{mL}$) of diaminobenzidine (DAB) which is a substrate of peroxidase and 5 μL (0.03%) of H_2O_2 (produced by VECTOR) is added to the sample, and the resultant is allowed to react for about 5 to 10 minutes in the dark. Coloring is checked sometimes.

(15) Washing once (for 5 minutes) with 100 mL of TBS

(16) Staining of nuclei of cells in blue with hematoxylin reagent

(17) Ethanol substitution, dropping xylene and a sealant, and seal with a cover glass

3. Materials

[0026] Prostate cancer operation samples extirpated in Yokohama City University Hospital and related hospitals and pre-operation needle biopsies (total 49 cases, breakdown was as follows:)

Cases where bone metastasis occurred within 3 to 5 years (27 cases)

Cases where bone metastasis did not occur in the period mentioned above (22 cases) Bone metastatic site samples of prostate cancer (6 cases)

4. Results

[0027] Immunostaining was performed on the prostate cancer tissue samples by immunohistochemistry with the antibody. The samples used were the needle biopsy tissue samples or the extirpated prostate samples of the cases (27 cases) where bone metastasis occurred during the follow-up period of 3 to 5 years (including the cases where bone metastasis was found at the first visit), and the cases (22 cases) where bone metastasis did not occur during the above-mentioned period. Bone metastatic site samples of prostate cancer (6 cases) were also stained, and evaluation at the metastatic site was also conducted.

[0028] As a result of immunohistochemical staining, in prostate cancer cases where bone metastasis occurred, positive image (brown) was observed in the primary focus and in the metastatic focus in the prostate cancer cells. In the staining pattern, strong staining was observed chiefly in the nuclei. Further, irrespective of histological malignancy (Gleason grade), in most of the bone metastasis cases, the results were positive and in most of the cases where bone metastasis did not occur, the results were negative.

[0029] The results of staining were classified into 3 grades, namely, negative, positive, and strongly positive by two or more pathologists. The negative grade was the cases where staining with the antibody was not observed; the strongly positive grade was the cases where strong staining with the antibody was observed; and the positive grade was the cases where staining with the antibody was observed, but the degree of staining was not so strong as the strongly positive grade.

[0030] The results are shown in Table 1 below and Fig. 1. As shown in Table 1 and Fig. 1, irrespective of the histological malignancy, in the cases where bone metastasis occurred, 19 cases were strongly positive grade, 8 cases were positive grade and 0 case was negative grade, so that the antibody reaction was positive in 100% of the cases. On the other hand, in the cases where bone metastasis did not occur, 1 case was strongly positive grade, 6 cases were positive grade and 15 cases were negative grade, so that most of them was negative grade. Since the follow-up period is short, it is thought that there is a possibility that in the strongly positive case and the positive cases in the cases where bone metastasis did not occur, bone metastasis may occur in the future. Further, in the site of bone metastasis, among the 6 cases, 3 cases were strongly positive grade and 3 cases were positive grade, so that the positive rate was 100% too. To determine whether there is a significant difference between the groups with bone metastasis and without bone metastasis in the results of staining with the antibody, a statistical test (chi square test) was carried out. As a result, in the bone metastasis-positive group, the staining with the antibody was significantly strongly positive or positive with a 99% significant difference ($P < 0.01$ ($\chi^2 = 31.2 > \chi^2(2; 0.01) = 9.21$). By these results, it was proved that the antibody can be used as a molecular marker (diagnostic reagent) for determining the probability that the prostate cancer will metastasized.

[0031]

Table 1

Immunohistochemical Staining	Number of Cases	
	without metastasis	with metastasis
Strongly Positive	1	19
Positive	6	8
Negative	15	0

EP 2 012 128 A1

(continued)

Immunohistochemical Staining	Number of Cases	
	without metastasis	with metastasis
Total	22	27

5

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> Yokohama City University
 <120> Method for predicting probability of metastasis of prostate cancer and
 diagnostic drug therefor
 <130> 06PF342-PCT
 10 <160> 3
 <170> PatentIn version 3.1
 <210> 1
 <211> 1767
 <212> DNA
 15 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (80)..(1735)
 <223>
 20 <400> 1
 gaattccggc gaatggctcg tctgtagtgc acgccgctgg cccagctgag accccggccc 60
 cgccccggg accccggcc atg gac gaa ctg ttc ccc ctc atc ttc ccg gca 112
 Met Asp Glu Leu Phe Pro Leu Ile Phe Pro Ala
 1 5 10
 25 gag cca gcc cag gcc tct ggc ccc tat gtg gag atc att gag cag ccc 160
 Glu Pro Ala Gln Ala Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln Pro
 15 20 25
 aag cag cgg ggc atg cgc ttc cgc tac aag tgc gag ggg cgc tcc gcg 208
 Lys Gln Arg Gly Met Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala
 30 30 40
 ggc agc atc cca ggc gag agg agc aca gat acc acc aag acc cac ccc 256
 Gly Ser Ile Pro Gly Glu Arg Ser Thr Asp Thr Thr Lys Thr His Pro
 45 50 55
 35 acc atc aag atc aat ggc tac aca gga cca ggg aca gtg cgc atc tcc 304
 Thr Ile Lys Ile Asn Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile Ser
 60 65 70 75
 ctg gtc acc aag gac cct cct cac cgg cct cac ccc cac gag ctt gta 352
 Leu Val Thr Lys Asp Pro Pro His Arg Pro His Pro His Glu Leu Val
 80 85 90
 40 gga aag gac tgc cgg gat ggc ttc tat gag gct gag ctc tgc ccg gac 400
 Gly Lys Asp Cys Arg Asp Gly Phe Tyr Glu Ala Glu Leu Cys Pro Asp
 95 100 105
 cgc tgc atc cac agt ttc cag aac ctg gga atc cag tgt gtg aag aag 448
 Arg Cys Ile His Ser Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys
 45 110 115 120
 cgg gac ctg gag cag gct atc agt cag cgc atc cag acc aac aac aac 496
 Arg Asp Leu Glu Gln Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn
 125 130 135
 50 ccc ttc caa gtt cct ata gaa gag cag cgt ggg gac tac gac ctg aat 544
 Pro Phe Gln Val Pro Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn
 140 145 150 155
 gct gtg cgg ctc tgc ttc cag gtg aca gtg cgg gac cca tca ggc agg 592
 Ala Val Arg Leu Cys Phe Gln Val Thr Val Arg Asp Pro Ser Gly Arg

55

EP 2 012 128 A1

	160					165					170						
5	ccc	ctc	cgc	ctg	ccg	cct	gtc	ctt	cct	cat	ccc	atc	ttt	gac	aat	cgt	640
	Pro	Leu	Arg	Leu	Pro	Pro	Val	Leu	Pro	His	Pro	Ile	Phe	Asp	Asn	Arg	
				175					180					185			
	gcc	ccc	aac	act	gcc	gag	ctc	aag	atc	tgc	cga	gtg	aac	cga	aac	tct	688
	Ala	Pro	Asn	Thr	Ala	Glu	Leu	Lys	Ile	Cys	Arg	Val	Asn	Arg	Asn	Ser	
			190					195					200				
10	ggc	agc	tgc	ctc	ggt	ggg	gat	gag	atc	ttc	cta	ctg	tgt	gac	aag	gtg	736
	Gly	Ser	Cys	Leu	Gly	Gly	Asp	Glu	Ile	Phe	Leu	Leu	Cys	Asp	Lys	Val	
		205					210					215					
	cag	aaa	gag	gac	att	gag	gtg	tat	ttc	acg	gga	cca	ggc	tgg	gag	gcc	784
15	Gln	Lys	Glu	Asp	Ile	Glu	Val	Tyr	Phe	Thr	Gly	Pro	Gly	Trp	Glu	Ala	
	220					225					230					235	
	cga	ggc	tcc	ttt	tcg	caa	gct	gat	gtg	cac	cga	caa	gtg	gcc	att	gtg	832
	Arg	Gly	Ser	Phe	Ser	Gln	Ala	Asp	Val	His	Arg	Gln	Val	Ala	Ile	Val	
					240					245					250		
20	ttc	cgg	acc	cct	ccc	tac	gca	gac	ccc	agc	ctg	cag	gct	cct	gtg	cgt	880
	Phe	Arg	Thr	Pro	Pro	Tyr	Ala	Asp	Pro	Ser	Leu	Gln	Ala	Pro	Val	Arg	
				255					260					265			
	gtc	tcc	atg	cag	ctg	cgg	cgg	cct	tcc	gac	cgg	gag	ctc	agt	gag	ccc	928
25	Val	Ser	Met	Gln	Leu	Arg	Arg	Pro	Ser	Asp	Arg	Glu	Leu	Ser	Glu	Pro	
			270					275					280				
	atg	gaa	ttc	cag	tac	ctg	cca	gat	aca	gac	gat	cgt	cac	cgg	att	gag	976
	Met	Glu	Phe	Gln	Tyr	Leu	Pro	Asp	Thr	Asp	Asp	Arg	His	Arg	Ile	Glu	
		285					290					295					
	gag	aaa	cgt	aaa	agg	aca	tat	gag	acc	ttc	aag	agc	atc	atg	aag	aag	1024
30	Glu	Lys	Arg	Lys	Arg	Thr	Tyr	Glu	Thr	Phe	Lys	Ser	Ile	Met	Lys	Lys	
	300					305					310					315	
	agt	cct	ttc	agc	gga	ccc	acc	gac	ccc	cgg	cct	cca	cct	cga	cgc	att	1072
	Ser	Pro	Phe	Ser	Gly	Pro	Thr	Asp	Pro	Arg	Pro	Pro	Pro	Arg	Arg	Ile	
					320					325					330		
35	gct	gtg	cct	tcc	cgc	agc	tca	gct	tct	gtc	ccc	aag	cca	gca	ccc	cag	1120
	Ala	Val	Pro	Ser	Arg	Ser	Ser	Ala	Ser	Val	Pro	Lys	Pro	Ala	Pro	Gln	
				335					340					345			
	ccc	tat	ccc	ttt	acg	tca	tcc	ctg	agc	acc	atc	aac	tat	gat	gag	ttt	1168
40	Pro	Tyr	Pro	Phe	Thr	Ser	Ser	Leu	Ser	Thr	Ile	Asn	Tyr	Asp	Glu	Phe	
			350					355					360				
	ccc	acc	atg	gtg	ttt	cct	tct	ggg	cag	atc	agc	cag	gcc	tcg	gcc	ttg	1216
	Pro	Thr	Met	Val	Phe	Pro	Ser	Gly	Gln	Ile	Ser	Gln	Ala	Ser	Ala	Leu	
			365				370					375					
45	gcc	ccg	gcc	cct	ccc	caa	gtc	ctg	ccc	cag	gct	cca	gcc	cct	gcc	cct	1264
	Ala	Pro	Ala	Pro	Pro	Gln	Val	Leu	Pro	Gln	Ala	Pro	Ala	Pro	Ala	Pro	
	380					385					390					395	
	gct	cca	gcc	atg	gta	tca	gct	ctg	gcc	cag	gcc	cca	gcc	cct	gtc	cca	1312
	Ala	Pro	Ala	Met	Val	Ser	Ala	Leu	Ala	Gln	Ala	Pro	Ala	Pro	Val	Pro	
				400						405					410		
50	gtc	cta	gcc	cca	ggc	cct	cct	cag	gct	gtg	gcc	cca	cct	gcc	ccc	aag	1360
	Val	Leu	Ala	Pro	Gly	Pro	Pro	Gln	Ala	Val	Ala	Pro	Pro	Ala	Pro	Lys	
				415				420						425			
55	ccc	acc	cag	gct	ggg	gaa	gga	acg	ctg	tca	gag	gcc	ctg	ctg	cag	ctg	1408
	Pro	Thr	Gln	Ala	Gly	Glu	Gly	Thr	Leu	Ser	Glu	Ala	Leu	Leu	Gln	Leu	

EP 2 012 128 A1

	430		435		440													
5	cag	ttt	gat	gat	gaa	gac	ctg	ggg	gcc	ttg	ctt	ggc	aac	agc	aca	gac	1456	
	Gln	Phe	Asp	Asp	Glu	Asp	Leu	Gly	Ala	Leu	Leu	Gly	Asn	Ser	Thr	Asp		
		445					450					455						
	cca	gct	gtg	ttc	aca	gac	ctg	gca	tcc	gtc	gac	aac	tcc	gag	ttt	cag	1504	
	Pro	Ala	Val	Phe	Thr	Asp	Leu	Ala	Ser	Val	Asp	Asn	Ser	Glu	Phe	Gln		
	460					465					470					475		
10	cag	ctg	ctg	aac	cag	ggc	ata	cct	gtg	gcc	ccc	cac	aca	act	gag	ccc	1552	
	Gln	Leu	Leu	Asn	Gln	Gly	Ile	Pro	Val	Ala	Pro	His	Thr	Thr	Glu	Pro		
					480					485					490			
	atg	ctg	atg	gag	tac	cct	gag	gct	ata	act	cgc	cta	gtg	aca	ggg	gcc	1600	
	Met	Leu	Met	Glu	Tyr	Pro	Glu	Ala	Ile	Thr	Arg	Leu	Val	Thr	Gly	Ala		
15				495					500					505				
	cag	agg	ccc	ccc	gac	cca	gct	cct	gct	cca	ctg	ggg	gcc	ccg	ggg	ctc	1648	
	Gln	Arg	Pro	Pro	Asp	Pro	Ala	Pro	Ala	Pro	Leu	Gly	Ala	Pro	Gly	Leu		
			510					515					520					
20	ccc	aat	ggc	ctc	ctt	tca	gga	gat	gaa	gac	ttc	tcc	tcc	att	gcg	gac	1696	
	Pro	Asn	Gly	Leu	Leu	Ser	Gly	Asp	Glu	Asp	Phe	Ser	Ser	Ile	Ala	Asp		
		525					530					535						
	atg	gac	ttc	tca	gcc	ctg	ctg	agt	cag	atc	agc	tcc	taa	gggggtgacg	1745			
	Met	Asp	Phe	Ser	Ala	Leu	Leu	Ser	Gln	Ile	Ser	Ser						
25	540					545					550							
	cctg	ccctcc	ccagag	cact	gg	1767												
	<210>	2																
	<211>	551																
30	<212>	PRT																
	<213>	Homo sapiens																
	<400>	2																
	Met	Asp	Glu	Leu	Phe	Pro	Leu	Ile	Phe	Pro	Ala	Glu	Pro	Ala	Gln	Ala		
35	1				5					10					15			
	Ser	Gly	Pro	Tyr	Val	Glu	Ile	Ile	Glu	Gln	Pro	Lys	Gln	Arg	Gly	Met		
				20					25					30				
40	Arg	Phe	Arg	Tyr	Lys	Cys	Glu	Gly	Arg	Ser	Ala	Gly	Ser	Ile	Pro	Gly		
		35						40					45					
	Glu	Arg	Ser	Thr	Asp	Thr	Thr	Lys	Thr	His	Pro	Thr	Ile	Lys	Ile	Asn		
		50					55					60						
45	Gly	Tyr	Thr	Gly	Pro	Gly	Thr	Val	Arg	Ile	Ser	Leu	Val	Thr	Lys	Asp		
	65					70					75					80		
	Pro	Pro	His	Arg	Pro	His	Pro	His	Glu	Leu	Val	Gly	Lys	Asp	Cys	Arg		
50					85					90					95			
	Asp	Gly	Phe	Tyr	Glu	Ala	Glu	Leu	Cys	Pro	Asp	Arg	Cys	Ile	His	Ser		
				100					105					110				
55																		

EP 2 012 128 A1

Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys Arg Asp Leu Glu Gln
 115 120 125
 5 Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn Pro Phe Gln Val Pro
 130 135 140
 10 Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn Ala Val Arg Leu Cys
 145 150 155 160
 Phe Gln Val Thr Val Arg Asp Pro Ser Gly Arg Pro Leu Arg Leu Pro
 165 170 175
 15 Pro Val Leu Pro His Pro Ile Phe Asp Asn Arg Ala Pro Asn Thr Ala
 180 185 190
 20 Glu Leu Lys Ile Cys Arg Val Asn Arg Asn Ser Gly Ser Cys Leu Gly
 195 200 205
 Gly Asp Glu Ile Phe Leu Leu Cys Asp Lys Val Gln Lys Glu Asp Ile
 210 215 220
 25 Glu Val Tyr Phe Thr Gly Pro Gly Trp Glu Ala Arg Gly Ser Phe Ser
 225 230 235 240
 30 Gln Ala Asp Val His Arg Gln Val Ala Ile Val Phe Arg Thr Pro Pro
 245 250 255
 Tyr Ala Asp Pro Ser Leu Gln Ala Pro Val Arg Val Ser Met Gln Leu
 260 265 270
 35 Arg Arg Pro Ser Asp Arg Glu Leu Ser Glu Pro Met Glu Phe Gln Tyr
 275 280 285
 40 Leu Pro Asp Thr Asp Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg
 290 295 300
 Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly
 305 310 315 320
 45 Pro Thr Asp Pro Arg Pro Pro Arg Arg Ile Ala Val Pro Ser Arg
 325 330 335
 50 Ser Ser Ala Ser Val Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr
 340 345 350
 Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe
 355 360 365
 55 Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro
 370 375 380

EP 2 012 128 A1

Gln Val Leu Pro Gln Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val
 385 390 395 400
 5 Ser Ala Leu Ala Gln Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly
 405 410 415
 10 Pro Pro Gln Ala Val Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly
 420 425 430
 Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu
 435 440 445
 15 Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr
 450 455 460
 20 Asp Leu Ala Ser Val Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln
 465 470 475 480
 Gly Ile Pro Val Ala Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr
 485 490 495
 25 Pro Glu Ala Ile Thr Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp
 500 505 510
 30 Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu
 515 520 525
 Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala
 530 535 540
 35 Leu Leu Ser Gln Ile Ser Ser
 545 550
 <210> 3
 <211> 12
 40 <212> PRT
 <213> Artificial
 <220>
 <223> peptide fragment used as an immunogen
 45 <400> 3
 Val Phe Arg Thr Pro Pro Tyr Ala Asp Pro Ser Cys
 1 5 10
 50

Claims

- 55
1. A method for determining probability that a prostate cancer will metastasize, said method comprising measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, said human NF-κB-p65/RelA being contained in a prostate tissue separated from human.

EP 2 012 128 A1

2. The method according to claim 1, carried out by an immunoassay using an antibody or an antigen-binding fragment thereof, said antibody undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is phosphorylated but not undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is not phosphorylated.

5

3. The method according to claim 2, wherein said immunoassay is immunohistochemical staining.

4. The method according to according to any one of claims 1 to 3, wherein the metastasis is bone metastasis.

10

5. A diagnostic reagent for determining probability that a prostate cancer will metastasize, said reagent comprising an antibody or an antigen-binding fragment thereof, said antibody undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is phosphorylated but not undergoing antigen-antibody reaction with human NF- κ B-p65/RelA in which 254th amino acid threonine is not phosphorylated.

15

20

25

30

35

40

45

50

55




Fig.1

EP 2 012 128 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/057048

<p>A. CLASSIFICATION OF SUBJECT MATTER G01N33/574 (2006.01) i</p> <p>According to International Patent Classification (IPC) or to both national classification and IPC</p>																	
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) G01N33/574</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2007 Kokai Jitsuyo Shinan Koho 1971-2007 Toroku Jitsuyo Shinan Koho 1994-2007</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)</p>																	
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>JP 2002-511564 A (DIADEXUS INC.), 16 April, 2002 (16.04.02), & EP 1057024 A & WO 99/042830 A & CA 2320843 A</td> <td>1-5</td> </tr> <tr> <td>A</td> <td>JP 2004-532390 A (Pintex Pharmaceuticals, Inc.), 21 October, 2004 (21.10.04), & US 2003-0073096 A & EP 1446044 A & WO 2002/064015 A & CA 2437784 A</td> <td>1-5</td> </tr> </tbody> </table> <p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p> <p>* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family</p> <table border="1"> <tr> <td>Date of the actual completion of the international search 13 July, 2007 (13.07.07)</td> <td>Date of mailing of the international search report 31 July, 2007 (31.07.07)</td> </tr> <tr> <td>Name and mailing address of the ISA/ Japanese Patent Office</td> <td>Authorized officer</td> </tr> <tr> <td>Facsimile No.</td> <td>Telephone No.</td> </tr> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	JP 2002-511564 A (DIADEXUS INC.), 16 April, 2002 (16.04.02), & EP 1057024 A & WO 99/042830 A & CA 2320843 A	1-5	A	JP 2004-532390 A (Pintex Pharmaceuticals, Inc.), 21 October, 2004 (21.10.04), & US 2003-0073096 A & EP 1446044 A & WO 2002/064015 A & CA 2437784 A	1-5	Date of the actual completion of the international search 13 July, 2007 (13.07.07)	Date of mailing of the international search report 31 July, 2007 (31.07.07)	Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	Facsimile No.	Telephone No.
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
A	JP 2002-511564 A (DIADEXUS INC.), 16 April, 2002 (16.04.02), & EP 1057024 A & WO 99/042830 A & CA 2320843 A	1-5															
A	JP 2004-532390 A (Pintex Pharmaceuticals, Inc.), 21 October, 2004 (21.10.04), & US 2003-0073096 A & EP 1446044 A & WO 2002/064015 A & CA 2437784 A	1-5															
Date of the actual completion of the international search 13 July, 2007 (13.07.07)	Date of mailing of the international search report 31 July, 2007 (31.07.07)																
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer																
Facsimile No.	Telephone No.																

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **WAKAI K.** Descriptive epidemiology of prostate cancer. *Japan and Western countries Nippon Rinsho*, February 2005, vol. 63 (2), 207-12 [0006]
- **LOBERG RD ; GAYED BA ; OLSON KB ; PIENTA KJ.** A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. *J Cell Biochem.*, 15 October 2005, vol. 96 (3), 439-46 [0006]
- **HUANG S ; PETTAWAY CA ; UEHARA H ; BUCANA CD ; FIDLER IJ.** Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. *Oncogene*, 12 July 2001, vol. 20 (31), 4188-97 [0006]
- **LESSARD L ; BEGIN LR ; GLEAVE ME ; MES-MASSON AM ; SAAD F.** Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. *Br J Cancer.*, 31 October 2005, vol. 93 (9), 1019-23 [0006]
- **RYO A ; SUIZU F ; YOSHIDA Y ; PERREM K ; LIOU YC ; WULF G ; ROTTAPPEL R ; YAMAOKA S ; LU KP.** Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. *Mol Cell*, December 2003, vol. 12 (6), 1413-26 [0006]